

# EU Enforcement: Update on Unannounced Audit Program Progress and Results.

Paul Brooks  
Senior Vice President  
BSI Healthcare Solutions

# Three Directives become Two Regulations

- Direct entry into force
  - Three year transition period for MDD/AIMD
  - Three or five year transition period for IVD\*
- Regulation should result in more consistent application

\*Parliament proposed three year transition for IVDR / industry lobbying for five year



# Changes to the EU System Already Implemented

# Triggers for Short Term Changes to the System

- Discovery of a 16 year fraud in PIP breast implants using low quality “industrial grade” silicon oil
- Stress test performed by EU Commission
- Determined that changes were needed to improve early detection and prevent this type of incident
- Other high profile vigilance cases with hips, pelvic floor meshes, pacemaker leads, etc.
- Outcome: short term changes to the system
  - **Immediate Actions**
  - **Commission Regulation: How Competent Authorities control Notified Bodies**
  - **Commission Recommendation: How Notified Bodies audit Manufacturers**



# 24 September 2013

**COMMISSION  
IMPLEMENTING  
REGULATION (EU)  
No 920/2013**

of 24 September 2013 on  
**the designation and the  
supervision of notified  
bodies**

under Council Directive 90/385/EEC on active  
implantable medical devices and Council  
Directive 93/42/EEC on medical devices

**Directs Competent  
Authorities how to control  
Notified Bodies**

**COMMISSION  
RECOMMENDATION  
(2013/473/EU)**

of 24 September 2013 on the  
**audits and assessments  
performed by notified  
bodies**

in the field of medical devices




**Directs Notified Bodies how  
to audit Manufacturers**

**Effective from Jan 2014**

# Impact of Commission Implementing Regulation 920/2013 on the designation and the supervision of notified bodies: Criteria to be met for the designation of NB

Requirements	Impact
Joint Audits of NBs by Designating Authority, Commission (FVO) plus two other CAs	<ul style="list-style-type: none"> <li>NBs and Designating Authorities under scrutiny</li> <li>Highlights different approaches in Member States</li> <li>More scrutiny of competency requirements, in-house clinicians, qualifications</li> <li>Processes and procedures clarified</li> <li>NBs withdrawing – check NANDO, ask your CA</li> </ul> 
NB Designation valid for a maximum of five years	<ul style="list-style-type: none"> <li>No impact yet; will need CA resource</li> <li>Consistent with CE certification cycle</li> </ul> 
Extensions and Renewals follow the same procedure as Designations	<ul style="list-style-type: none"> <li>Helps consistency; will need CA resource</li> </ul> 
NBs subject to renewal by 14 October 2016	<ul style="list-style-type: none"> <li>Helps consistency; requires CA resource</li> </ul>
Designating Authorities shall have sufficient number of competent personnel	<ul style="list-style-type: none"> <li>Have they the qualified resource to deliver?</li> </ul> 

## Impact of Com. Recommendation (2013/473/EU) on audits and assessments performed by NBs – Items to be verified by NB during an audit

Requirements	Impact
Annex I: Criteria for NBs performing design dossier and type examinations 	<ul style="list-style-type: none"><li>• Mainly reinforcement of current good practice</li><li>• Increased need for clinical studies, less reliance on equivalence argument</li><li>• Will clarify time needed for reviews</li></ul>
Annex II: Criteria for NBs performing QMS assessments	<ul style="list-style-type: none"><li>• Mainly reinforcement of current good practice</li></ul>
Annex III: Unannounced visits to manufacturers, "critical subcontractors" or "crucial suppliers", in addition to planned audits 	<ul style="list-style-type: none"><li>• Completely new requirement needing extra product and QMS assessors</li><li>• Significant increase in NB workload and resources</li><li>• IAF rules require planned audit schedules so no scope for substitution</li><li>• Gone well in general</li><li>• Some SMEs feeling burden is disproportionate</li></ul> 

# EU Unannounced Visits: The Requirements



# Articles

2) Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the Member States relating to implantable medical devices ( 1 ), Council Directive 90/269/EEC of 14 June 1990 on the approximation of the laws, regulations, administrative provisions and directives of the Member States relating to the minimum health and safety requirements for the use of work equipment ( 2 ),

Directive 98/79/EC of the Council of 27 October 1998 on medical devices ( 3 ), contain certain provisions with regard to the audits, assessments *and unannounced audits performed by notified bodies in the field of medical devices.*

The legal provision exists in the current medical directives (MDD, AIMD & IVDD)

# Articles

5) Subject to the respective conformity assessment procedure, notified bodies perform product assessments and quality system assessments.

According to the standard, differentiate between these two types of assessments.

continuous conformity assessments, notified bodies should perform audits *in addition* to product assessments and quality system assessments.

**Unannounced Visits IN ADDITION TO product & QMS Assessments**

# Articles

*11) In the absence of established practice for unannounced audits it is important to determine the practicalities for such audits, as well as to provide advice on the arrangements needed for facilitating these audits.*

**Make Unannounced Audits an established practice**



# 1. PURPOSE

To facilitate the *consistent application* of the conformity assessment provisions contained in Directive 90/385/EEC, Directive 93/42/EEC and Directive 93/79/EC, the notified bodies should apply the *BSI Recommendation* when they perform the system assessments.

By providing general guidance, system assessments and unannounced audits, the *BSI Recommendation* should facilitate the work of the notified bodies *as well as the Member States' evaluation thereof*.

Consistency of Notified Bodies application and Competent Authority evaluation

## 2. GENERAL GUIDELINES FOR AUDITS AND ASSESSMENTS

c) To verify the day-to-day compliance with legal obligation, the bodies should, in addition to the initial audits, visit the

manufacture efficient charge

ensuring

('critical subcontractor

components or of the entire assembly

supplier') without prior notice ('unannounced

audits') in accordance with Annex III.

In addition to... regular visits  
Unannounced Visit can be at the  
manufacturer or critical subcontractor or  
crucial supplier (or both – more later)

### 3. FOLLOW-UP

*Member States should draw this Recommendation to the attention of the notified bodies in the field of medical devices and should supervise the practice of notified bodies with respect to this Recommendation. They should evaluate the notified bodies' implementation of the Recommendation. They should also monitor the unannounced audits of notified bodies, the designations of bodies and on request the withdrawal of designations.*

**Notified Bodies will be assessed to ensure we are implementing the requirements of the Commission Recommendation**



## *Annex III - Unannounced Audits*

- Unpredictable additional visit - at least once

per 3rd year

- At least one day by two assessors
- Increased frequency for 'high risk' or for non-

- Increased frequency, compliant or specific reasons to suspect non-

- Unpredictable additional visit - at least once per 3rd year
- At least one day by two assessors
- Increased frequency for 'high risk' or for non-compliant or specific reasons to suspect non-conformities

## Annex III - Unannounced Audits

2. Notified bodies may, instead of or in addition to visiting the manufacturer, visit one or more of the premises of the manufacturer's subcontractors, if this is likely to ensure more efficient control.

- Visits not only to the manufacturer
- Also to critical subcontractors or crucial suppliers if this is likely to ensure more efficient control.

Note: "instead of or in addition to"



## Annex III - Unannounced Audits

3. Within the context of such unannounced audits, the notified bodies should check a recently produced adequate sample, preferably a device taken from the ongoing manufacturing process, for its conformity with the requirements of the relevant standards.

The notified body should document the results of the check and the device checked, and the components of the device checked, and the components of the device checked, and the components of the device checked.

The notified body should check the conformity of the device with the requirements of the relevant standards. To prepare for the check, the notified body should check the conformity of the device with the requirements of the relevant standards.

The notified body should check the conformity of the device with the requirements of the relevant standards. To prepare for the check, the notified body should check the conformity of the device with the requirements of the relevant standards.

The notified body should check the conformity of the device with the requirements of the relevant standards. To prepare for the check, the notified body should check the conformity of the device with the requirements of the relevant standards.

The notified body should check the conformity of the device with the requirements of the relevant standards. To prepare for the check, the notified body should check the conformity of the device with the requirements of the relevant standards.

The notified body should check the conformity of the device with the requirements of the relevant standards. To prepare for the check, the notified body should check the conformity of the device with the requirements of the relevant standards.

### Focus of Visit =

- Ongoing manufacture
- Legal requirements
- Manufacturing link to technical file
- Product identification & traceability
- Verification of components
- Witness testing of product

## Annex III - Unannounced Audits

5) No  
manu  
and 3  
unann  
for the  
require  
least t  
specifi  
assembl  
Among  
which  
safety r

+ At least two of the following critical processes:-

- Design control
- Establishment of material specifications
- Purchasing and control of incoming material
- Assembling
- Sterilisation
- Batch-release
- Packaging
- Product quality control



## *Annex III – General advice...*

- Unannounced audits in premises of the manufacturer
- Contractual arrangements
- Travel & Visas
- Manufacturers to continuously inform the notified bodies when devices will not be manufactured
- Financial compensation for the audits including device acquisition, testing and security arrangements

# BSI Implementation

# Who?

- Commission Recommendation specifies at least two assessors
- BSI Assessment Team
  - One QMS Assessor (Client Manager)
  - One Product Technical Specialist
- In advance briefing preparation by the Scheme Manager
- Often not the regular assessor(s)



# Where?

Legal Manufacturer?

*YES if all or some manufacturing , design or test activities performed onsite for all or some products*



Critical Subcontractor or Crucial Supplier?

*YES, for virtual manufacturers*

# Where?

*"...if this is likely to ensure more efficient control... in particular if the main part of the design development, manufacturing, testing or another crucial process is located with the subcontractor or supplier."*

## Critical Subcontractor

E.g. Manufacturer of finished devices, key sub-assembly or significant components. Regulatory responsibility and / or activities essential for ensuring compliance with legal requirements. Design or software development, sterilisation, sterile packaging.

## Crucial Supplier

E.g. Critical raw materials such as silicone gel component for an implant, animal tissue for use in heart valve. Proprietary items.



# What information should we have on file?

- Facility Details

Access details: Hours of operation, contact names & phone numbers, PPE / Health & Safety requirements, language skills on site, shutdown periods etc.

- Critical Subcontractors & Crucial Suppliers (CS/CS)

Details of device types, activities performed & frequency + all above



# How often?

## Per Commission Recommendation & NB Code of Conduct

Minimum frequency in number of years for an unannounced visit	Classification			
	Is / Im IVD self test	Ila	Ilb	III / AIMD IVD List A
Normal conditions	3 yr	3 yr	3 yr	2 yr
If the device bears high risk	2 yr	2 yr	1 yr	1 yr
Devices that are often non-compliant	2 yr	2 yr	1 yr	1 yr
Specific reasons for suspicion	2 yr	2 yr	1 yr	1 yr

As frequently as needed

Version 3.2 – 22 July 2014

# For how long?

- Most Manufacturers
  - Including small & medium sized facilities
  - One day by two auditors
- Very Large Manufacturers
  - Several hundred employees +
  - Four man-days (or more in extreme cases). Likely two assessors for two days
  - Or an increase in frequency of visits





# What happens on the day?

- Arrival


BSI Assessors present an introduction / overview letter referencing the objective, EC Certificate(s), location to be assessed, date and assessment team

- Identification

The letter contains a link to the BSI website which contains names and photos of all assessors authorized to conduct Unannounced Audits for BSI



# What happens on the day?



BSI Assessors arrive onsite and present identification (letter and weblink)  
Request to speak to allocated contact or the most senior person on site  
Explanation of visit within brief opening meeting



Audit team progress swiftly to manufacturing area

Assessment team work together to audit all elements specified in the Commission Recommendation and identify areas / processes for further audit as part of the visit



Brief closing meeting, with details of findings where possible

Report will be provided within approximately one week

Follow up of any non-conformities through normal audit processes

# What happens on the day for a CS/CS?

BSI Assessors arrive onsite and present identification (letter and weblink)  
**Advise the CS/CS to contact their customer (the legal manufacturer)**  
Request to speak to all relevant contact or the most senior person on site  
Explanation of visit within brief opening meeting

Audit team progress swiftly to manufacturing area  
**Assessment of agreement / procedures / specifications between legal manufacturer & CS/CS**  
Assessment team work together to audit all elements specified in the Commission Recommendation and identify areas / processes for further audit as part of the visit

**Brief closing meeting, with permission / phone attendance of Legal Manufacturer & details of findings where possible**  
Report will be provided within approximately one week  
**Report provided to Legal Manufacturer within approx one week**  
Follow up of non-conformities via normal audit processes (at any location)

# What happens on the day if...?

- **No manufacturing or other processes ongoing?**
  - Review applicable evidence? E.g. Recent activity, warehouse stock, physical areas used, i.e. manufacturing, design, records etc and associated documentation
  - If CS/CS (& within limits of confidentiality) review similar activities/processes/areas
  - Assessment team judgement to a recommendation on audit validity
- **Audit team is refused or denied access**
  - Assessors complete report providing full details of situation encountered
  - Directly inform BSI Scheme Manager (& BSI notify Legal Manufacturer if CS/CS)
  - Note – any refusal or non co-operation will lead to review & follow-up action
  - Potential escalation to certificate scope reduction, suspension or cancellation

# BSI Experience to Date



# Timelines



---

March 2014

BSI trial period

Several Unannounced Audits conducted as trials across a range of companies and devices

---

April 2014

BSI live with routine Unannounced Audits (per European Competent Authorities expectations)

Small volume conducted

---

May – June  
2014

Global roll-out of internal training (5 events and 140 people)

Finalized practises, polices and procedures

---

July 2014 →

Full global roll out and ramp up, with significant volume of routine Unannounced Audits across remainder of 2014

+ Continuous internal review, policy finalization and refinement

---

# What did we learn?

- So far all were ready, including small manufacturers
- Some surprise (from auditees) at:-
  - The assessment team working together
  - No detailed assessment agenda
  - Different focus to normal visits. i.e. more on product, less on supporting QMS processes (No routine coverage of Management Review, Internal Audit, CAPA etc)
  - Having a visit so soon!
- Feedback indicated a more positive experience than expected!



# What did we learn? Key Points

- Unusual situations encountered
  - Manufacture site moving or moved
  - Re-modellers in facility
  - Audit from a national regulator ongoing
  - CE Certificate about to be cancelled
- Our procedures & training emphasise the importance of “speedy” access to manufacturing
- Please help... no long factory tours or routing, cups of coffee (can be later), network passwords, navigation / access issues



# What happened on the day?

- **Assessment Agenda**
  - BSI Assessors have detailed briefing but no fixed assessment agenda
  - Following arrival and overview meeting generally swift progress to manufacturing and / or final product areas
- **Typical Timings**
  - Morning spent in product areas, then working lunch
  - Afternoon finish production etc, then more office-based, documentation audit trails link to Technical Files & Dossiers
  - End of day wrap-up / brief closing meeting



# Are you ready? Have you?

1. Studied the requirement?
2. Factored additional costs into budgets?
3. Implemented processes and procedures for receiving visits?
4. Responded to requests from your NB?
5. Reviewed (or are reviewing) critical subcontractors & crucial suppliers contracts?
6. Communicated awareness across all staff and trained appropriate staff?
7. Practised?
8. Had one?! Did you conduct a post-audit review to learn from the experience?



# On the day

1. Ensure guide(s) assigned
2. Be aware of requirement & assist the auditors, e.g. get to manufacturing as soon as possible
3. Let the assessment team know of any concerns or issues (e.g. no CE devices in production that day, fire alarm planned)
4. Think ahead – remember likely need access to Technical Files / Design Dossiers for devices
5. Feel free to ask questions (will they break for lunch, approximate time to wrap-up etc)
6. Conduct (& share?) internal post audit review on any learnings – ready for next time?!



# BSI Resources

<http://medicaldevices.bsigroup.com/en-GB/our-services/Unannounced-audits-from-BSI/>

- Commission Recommendation
- e-Updates
- Webinar Details & Recordings
- Frequently Asked Questions

## How BSI can support you with unannounced audits

CE Marking Medical Devices - European Commission Recommendation of 24 September 2013 (2013/473/EU)

European medical device regulations are undergoing many significant changes that will impact manufacturers, suppliers, and Notified Bodies. One major and immediate change is the EU Commission requirement for Notified Bodies to conduct unannounced audits on manufacturers of CE marked products.



### Webinar - Unannounced Visits - Feb 2014

Watch a recording of our live webinar from Tuesday 11 February 2014 where we discussed the background, requirements and implementation of unannounced visits.

- › [Watch the webinar](#)
- › [Download the presentation](#)

### FAQs for unannounced audits

Download our FAQ document to understand why unannounced audits were introduced and how you can meet these new requirements.

- › [Download the unannounced audits FAQ \(294KB\)](#)

### EU Commission Recommendation

Read more about the EU Commission Recommendation published in the EU Official Journal - 24 September 2013.

- › [Read the EU Commission Recommendation](#)

# Any Questions

Paul Brooks

[paul.brooks@bsigroup.com](mailto:paul.brooks@bsigroup.com)

+1-703-464-1923







...making excellence a habit.<sup>TM</sup>